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ABSTRACT
Background: Low plasma total glutathione (tGSH) levels, elevated levels of oxidized glutathione (GSSG) and low ratios of  tGSH to
GSSG in autism were reported. Glutathione S-transferases (GST) are antioxidant enzymes that play important role in cellular
detoxification and the excretion of environmental pollutants including heavy metals. Glutathione S-transferase mu (GSTM1) and
Glutathione S-transferase theta (GSTT1) are known to be highly polymorphic. Homozygous deletions of these genes result in lack of
enzyme activity and impaired the ability to excrete metals including mercury. Combined effects of mercury (Hg) accumulation
coupled with decreased levels of antioxidants (low glutathione and antioxidant enzymes) contribute to the phenotypic presentation of
autism spectrum disorder (ASD). Association of GSTM1 null genotype with autism has been reported. Therefore the preliminary
study was performed to investigate the role of GSTM1 null and GSTT1 null as risk factor of ASD associated with phenotype
expression.
Method: Fifty one ASD patients were recruited from special need & autism school and 45 controls from Semarang & Solo. Blood
veins samples were collected and genomic DNA was extracted by salting-out method in CEBIOR Semarang. Genotyping for GSTM1
and GSTT1 gene was done in UMBI Malaysia. Multiplex PCR was performed and PCR products were separated on 1.2 % agarose
gel, stained with ethidium bromide and visualized on UV transiluminator. GSTM1 & GSTT1 gene product is about 625 bp and 459
bp. Absence of GSTM1 and GSTT1 gene band was interpreted as GSTM1 null & GSTT1 null.
Results: The frequency of GSTM1 null and GSTT1 null in ASD higher compared with control group but the difference is not
statistically significant (p=0.357, OR=0.504; 95% CI 0.117-2.168 and p=0.364, OR=0.674; 95% CI 0.287-1.580). There is also no
statistically different in the distribution of GSTM1 null and GSTT1 null between mild to moderately autistic and severely autistic
(p=0.983, OR=0.980; 95% CI 0.158-6.095 and p=0.439, OR=1.633; 95% CI 0.471-5.656).
Conclusion: GSTM1 null and GSTT1 null are not risk factor of ASD. Further investigations are needed with a bigger sample size,
analyzing multiple GST genes and GST activity determination to find out the gene susceptibility of ASD and factors that contribute to
the phenotype expression of ASD.
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ABSTRAK
Apakah GSTM1 Null dan GSTT1 Null merupakan faktor risiko autism spectrum disorder? Studi pendahuluan
Latar belakang: Pada autism ditemukan bahwa glutathion total plasma (tGSH) rendah, oxidized glutathione (GSSG) meningkat dan
rasio tGSH terhadap GSSG rendah. Glutathione s-transferase (GST) merupakan enzim antioksidan yang berperan penting dalam
proses detoksifikasi seluler dan ekskresi polutan lingkungan termasuk diantaranya logam berat. Polimorfisme gen GST mu (GSTM1)
dan GST theta (GSTT1) cukup tinggi. Delesi homozigot gen GSTM1 dan GSTT1 yang menyebabkan berkurang sampai tidak adanya
aktivitas enzim GST serta menurunnya level antioksidan berkontribusi terhadap risiko ASD. Oleh karena itu dilakukan penelitian
pendahuluan untuk mengetahui hubungan antara gen GSTM1 null dan GSTT1 null sebagai faktor risiko ASD dengan ekspresi
fenotip.
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Metode: Lima puluh satu pasien ASD dari SLB dan sekolah
autis serta 45 kontrol dari Semarang dan Solo diambil darah
vena, kemudian diekstraksi dengan metode salting-out di
CEBIOR Semarang. Pemeriksaan genotip gen GSTM1 &
GSTT1 dilakukan di UMBI Malaysia. Metode yang digunakan
adalah PCR multipleks, setelah itu produk PCR dipisahkan
pada 1,2% gel agarosa kemudian dicat dengan ethidium
bromida dan hasilnya dilihat menggunakan transiluminator
UV. Besar produk untuk GSTM1 & GSTT1 adalah 625 bp &
459 bp. Tidak adanya band untuk gen GSTM1 & GSTT1
diinterpretasikan sebagai GSTM1 null & GSTT1 null.
Hasil: Frekuensi gen GSTM1 null dan GSTT1 null pada ASD
lebih tinggi dibandingkan kontrol tetapi tidak ditemukan
perbedaan yang signifikan (p=0,357, OR=0,504; 95% CI
0,117-2,168 and p=0,364, OR=0,674; 95% CI 0,287-1,580).
Distribusi gen GSTM1 null dan GSTT1 null pada autis ringan
sedang dan autis berat juga tidak ditemukan perbedaan yang
signifikan secara statistik (p=0,983, OR=0,980; 95% CI
0,158-6,095 and p=0,439, OR=1,633; 95% CI 0,471-5,656).
Simpulan: GSTM1 null dan GSTT1 null bukan merupakan
faktor risiko ASD. Penelitian lebih lanjut sangat diperlukan
dengan jumlah sampel yang lebih besar, analisis gen GST
multipel dan pemeriksaan aktivitas GST untuk mendapatkan
gen faktor risiko ASD dan faktor-faktor yang mempengaruhi
ekspresi fenotip ASD.
INTRODUCTION
Autism spectrum disorder (ASD) is neurodevelopmental
disorder characterized by qualitative impairments in the
development of social and communication skills, often
accompanied by stereotyped and restricted patterns of
interests and behavior, with onset of impairment before
3 years of age.1 Epidemiological studies demonstrate
that the prevalence of autism has increased in recent
years2 and occurs four times as frequently in males as
females.3 It is currently estimated that autism affects as
many as 1 out of 150 children in the United States4 and
14.8 per 10,000 in Asia Prevalence of ASD in Asia was
14.8 per 10,000 from 1980 to present.5
Investigators suggested that ASD may result from an
interaction between genetic and environmental factors,
with oxidative stress as a mechanism linking these risk
factors.6 There is evidence supporting the role of
oxidative stress in autism7 that affect brain development
during gestation or possibly after gestation, contributing
to expression of autism.8 Some reviews support the
hypothesis that oxidative stress contributed to the
pathology of autism.9,10
Glutathione S-transferases are antioxidant enzymes that
play important role in cellular detoxification and the
excretion of environmental pollutants including many
carcinogens and also in protection against oxidative
stress11,12, by its ability to conjugate glutathione (GSH)
with compounds containing an electrophilic
center.11,13,14 These enzymes detoxify a broad range of
substances including carcinogens, environmental toxins,
and drugs. At least seven distinct classes have been
identified: alpha (α), mu (µ), pi (π), sigma (σ), theta (θ),
kappa (κ), and zeta (ξ).13
Glutathione S-transferase mu (GSTM1) and glutathione
S-transferase theta (GSTT1) are known to be highly
polymorphic. This genetic variation may change an
individual’s susceptibility to carcinogens and toxins.11
Homozygous deletions of these genes, referred to as
GSTM1 null and GSTT1 null, respectively, result in
lack of enzyme activity.15 Subjects with at least one
functional allele for GSTM1 are designated as GSTM1
positive.13
Association of GSTM1 null genotype with autism has
been reported.16 Absence of the GSTM1 gene, resulting
in impaired enzyme activity, could lead to failure of
individuals with autism to detoxify xenobiotics.
Mercury (Hg) coupled with decreased levels of
antioxidants (low glutathione and antioxidant enzymes),
leading to the increased production of free radicals. This
can cause an increase in lipid peroxidation, protein
oxidation, and DNA oxidation that lead to increased
oxidative stress. All of that resulting in impaired
neuronal development, increased inflammatory
response, impaired energy production, cell death and
decreased synaptic efficiency. These combined effects
contribute to the phenotypic presentation of ASD.9
Therefore the preliminary study was conducted to
investigate the role of GSTM1 and GSTT1
polymorphism as risk factor of ASD associated with
phenotype expression.
MATERIALS AND METHODS
Subjects
This is case control study with total 96 subjects
comprised of 51 autism spectrum disorder subjects (48
males and 3 females; age range 4-18 years; mean 9.82
years) from special need and autism school and 45
unrelated healthy subjects 23 males and 22 females; age
range 4-17 years; mean 12.25 years) from Public School
in Semarang and Solo, Indonesia. Diagnosis of ASD
was according to DSM IV (diagnosis and statistical
manual of mental disorders, fourth edition) and
phenotype expression of ASD was determined using
childhood autism rating scale (CARS). This study was
conducted with informed consent of all subjects’ parent
and approved by institutional review committee from
the Medical Faculty Diponegoro University and Ethical
Clearance of Dr. Kariadi Hospital Semarang, Indonesia.
Research was done in Central Biomedical Research
(CEBIOR) Medical Faculty Diponegoro University,
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Indonesia and UKM Medical Molecular Biology
Institute (UMBI), Malaysia.
Genotyping
Blood vein samples were collected from both groups of
patients and controls in EDTA tubes. Genomic DNA
was extracted from peripheral blood leucocytes by
salting-out method. The purity and concentration of
DNA were quantified using nanodrop spectro-
photometer (ND 1000 spectrophotometer). Presence or
absence of GSTM1 and GSTT1 genes in genomic DNA
samples were detected by multiplex PCR technique. β-
globin gene was coamplified as positive internal control.
The multiplex PCR was performed in 25 µl reaction
volume containing 30-50 ng of DNA, 12.5 µl
HotStarTaq Master Mix (Qiagen) in which containing
of 1.25 units HotStarTaq DNA polymerase, 1x PCR
Buffer, 100 µM of each dNTP and 0.75 mM MgCl2.
Concentration for each primer is 0.2 µM. Primers
for GSTM1 gene (forward primer
5’-TCTGGGGAGGTTTGTTTTCA-3’ and reverse
primer 5’ TCT CCAAAATGTCCACACGA-3’),
GSTT1 gene (forward primer 5’-TTCCTTACTG
GTCCTCACATCTC-3’ and reverse primer
5’-TCACCGGATCATGGCCAGCA-3’) and β-globin
gene (forward primer
5’-GAGTCAAGGCTGAGAGATGCAGGA-3’ and
reverse primer
5’-CAATGTATCATGCCTCTTTGCACC-3’).
The PCR for GSTM1 gene was performed with an
initial denaturation 95OC for 4 minutes, followed by 35
cycles with denaturation at 95OC for 1 minute,
annealing at 50OC and extension at 72OC for 2 minutes.
Final extension was performed at 72OC for 10 minutes
and hold at 4OC. PCR for GSTT1 gene, same with
protocol above except the annealing temperature was
changed at 61OC.
PCR products were separated on 1.2% agarose gel,
stained with ethidium bromide and visualized on an UV
transiluminator. GSTM1 gene product is about 625 bp,
GSTT1 product is 459 bp and 850 bp for β-globin gene
as internal control. In the presence of GSTM1 and
GSTT1 gene band was interpreted as GSTM1 and
GSTT1 positive gene. Absence of GSTM1 and GSTT1
gene band was interpreted as GSTM1 null and GSTT1
null.
Statistical analysis
Statistical analysis was carried out using SPSS software
version 16.0 for Windows. Logistic regression test was
used to calculate the differences in genotype prevalence
and association between case and control groups. T-test
and Kruskal-Wallis test were used to analyze
association between CARS score and genotype. The
odds ratio (OR) and its 95% confidence interval (CI)
were used to illustrate the association. All tests were
two sided and p value <0.05 was considered statistically
significant.
RESULTS
The deletion polymorphisms for GSTM1 and GSTT1
were genotyped in 51 autism spectrum disorder cases
and 45 controls. The frequency of ASD is 48 male and 3
female, while in control group 23 male and 22 female.
Figure 1 and 2 shows the distribution of sex and age in
ASD and control group. Frequency of male patients of
ASD is higher than female, but in control group the
number of male and female almost the same. The
highest distribution of ASD patiens are in 4-10 years old
age group. Meanwhile, in control group is 12-15 years
old age group.
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Figure 1. Distribution of sex in ASD and control
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Figure 2. Distribution of age in ASD and control
Figure 3 shows the distribution of GSTM1 and GSTT1
gene in ASD and control. The frequency of both
GSTM1 null and GSTT1 null gene in ASD is higher
than control, meanwhile frequency of GSTM1 positive
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and GSTT1 positive almost the same between ASD and
control group. All female patients of ASD categorized
in mild to moderate autistic using CARS. Therefore
most of male ASD patients categorized in severe autistic
(Figure 4).
Figure 5 and 6 shows PCR result for GSTM1 and
GSTT1 gene. The presence of β globin gene (850 bp),
GSTM1 gene band (637 bp) and GSTT1 gene band (459
bp) is interpreted as GSTM1 and GSTT1 positive.
While absence of GSTM1 and GSTT1 band is
interpreted as GSTM1 null and GSTT1 null.
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Figure 3. Distribution of GSTM1 and GSTT1 gene in ASD
and control
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Figure 4. Distribution of sex according to phenotype
expression
The frequency of GSTM1 null in ASD higher compared
with control group but the difference is not statistically
significant (p=0.357, OR=0.504; 95% CI 0.117-2.168).
GSTT1 null genotype’s frequency compared with
control group is higher but also no significance different
(p=0.364, OR=0.674; 95% CI 0.287-1.580).
Additionally, combination of GSTM1 and GSTT1 was
not reach statistically significance among cases and
controls (p=0.299) [see Table 1].
Figure 5. PCR result for GSTM1 gene
Lane 1 : marker (ladder 1 kb)
Lane 2,4,6,7 : GSTM1 positive (+/+ or +/-)
Lane 3 & 5 : GSTM1 null (-/-)
Lane 8 : positive control
Lane 9 : blank
β globin : 850 bp; GSTM1 gene: 637 bp
Figure 6. PCR result for GSTT1 gene
Lane 1 : marker (ladder 100 bp)
Lane 2,3,5,7,10,11,12,14 : GSTT1 positive (+/+ or +/-)
Lane 4,6,8,9,13,15 : GSTT1 null (-/-)
Lane 16 : positive control; lane 17: blank
β globin : 850 bp; GSTT1 gene: 459 bp
Phenotype expression of ASD is represented by
childhood autism rating scale (CARS), divided into two
group as mild to moderately autistic and severely
autistic. There is no statistically different in the
distribution of GSTM1 null and GSTT1 null between
mild to moderately autistic and severely autistic
(p=0.983, OR=0.980; 95% CI 0.158-6.095 and p=0.439,
OR=1.633; 95% CI 0.471-5.656), that also found in
combination of GSTM1 and GSTT1 gene in which the
p value is 0.667. Statistical analysis for GSTM1 null,
GSTT1 null and combination of both gene compared
with CARS score also showed no significance different
(see Table 1).
850 bp
637 bp
850 bp
459 bp
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Table 1. Odd ratios (OR) and p value of GSTM1, GSTT1 and combination both genes in association with group and phenotype
expression
GSTM1 null GSTT1 null GSTM1/GSTT1
OR 95% CI p OR 95% CI p p
Group
a. ASD 0.504 0.117 - 2.168 0.357a 0.674 0.287 - 1.580 0.364a 0.299c
b. Control
CARS
a. Mild to moderately autistic 0.980 0.158 - 6.095 0.983a 1.633 0.471 - 5.656 0.439a 0.667c
b. Severely autistic
CARS score
GSTM1null 37.217 - 43.449 0.317b GSTT1null 34.779 - 39.554 0.157b 0.476d
Wild type    36.720 - 39.670 Wild type   37.604 - 40.815
a. Logistic regression c. Kendall tau
b. T-test d. Kruskal-Wallis
DISCUSSION
This is preliminary study that was carried out to
investigate the relationship between genetic poly-
morphisms of GSTT1, GSTM1 and phenotype
expression of autism spectrum disorder (ASD).
Autism spectrum disorder is a complex and multi-
factorial disease. It is difficult to identify single
elements that increase the risk. Autism may result from
a combination of genetic susceptibility (reduced ability
to remove metals including mercury or other neuro-
toxins from the system) and environmental exposure.
17-19 Several genes have been reported associated with
autism, including genes involved in methionine trans-
methylation and transsulfuration pathways. Poly-
morphism of reduced folate carrier I (RFC1) gene,
methylenetetrahydrofolate reductase (MTHFR), trans-
cobalamin II (TCN2), catechol-O-methyl-transferase
(COMT) and glutathione S-transferase mu 1 (GSTM1)16
was significantly increased among autistic children
compared to control.20
In the present study, we found that the frequency of the
GSTM1 null genotype in control groups was 6.7%,
quite different from previous study in Jakarta,
Indonesian population (55.6%)21 much lower than in
Caucasian population (42%-60%) and other Asians
population, in Japan 47.9%, Korea 52.2% and
Singapore 56.2%.22 The frequency of the GSTT1 null
genotype was 31.1% in our control population, similar
with Japan population (35.3%), lower than previous
study in Jakarta, Indonesian population (41.4%)21, in
Koreans (51.5 %) and Singapore population (51.9%)22,
but higher than in Europeans (22%) and in African-
Americans.23
Steven Buyske, et al. (2006) concluded an association
of the homozygous GSTM1 deletion genotype with
autism (p=0.028). Our study revealed that GSTM1 null
and GSTT1 null are not risk factor of ASD. There is no
significant association between GSTM1 and GSTT1
null gene with autism spectrum disorders (ASD),
although the distribution of these genes among ASD
higher than controls. The combination of GSTM1 null
and GSTT1 null also do not contribute to ASD risk in
this population.
The difference of result compared with others studies
could be the fact that this study conducted in different
race and population. Small total sample size is also the
limitation of the present study, although it has fulfilled
the sample size number requirement for statistical
analysis. Another explanation for the differents in
results is GST enzymes have a broad substrate overlap,
therefore decreased in expression level of one GST may
be compensated by increased expression of another. In
spite of that ASD is multifactorial disease, in which
there is complex environmental factors involved and
multiple genes participated, results in heterogeneity.
Therefore, this preliminary study needs further
investigations with increased sample size, multiple
genes and GST activity determination, to find out gene
susceptibility of ASD and factors that contribute to the
phenotype expression of ASD.
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